Mangalam Drugs & Organics
26.20
+1.24(+4.97%)
Market Cap₹41.47 Cr
PE Ratio-2.00
IndustryHealthcare
Company Performance:
1D+4.97%
1M-6.19%
6M-67.38%
1Y-77.77%
5Y-81.18%
View Company Insightsright
More news about Mangalam Drugs & Organics
06Oct 25
Manglam Group Launches ₹100 Crore Redevelopment Project in Mumbai's Borivali
Manglam Group has launched its first redevelopment project in Mumbai, Manglam Rajanigandha, in Borivali (West) with a ₹100 crore investment. The project, expected to generate ₹150 crore in revenue, will offer 80 two-bedroom apartments across 80,000 sq. ft. Half of the units will be allocated to existing tenants. The development includes amenities like landscaped green zones, a fitness center, and a jogging track. Homeowners will receive lifetime membership at the Mandapeshwar Civic Federation Gymkhana. The project is set for completion in June 2026.
06Sept 25
Mangalam Drugs Shares Pledged by Shree Kishoriju Trading for Debt Security
Shree Kishoriju Trading and Investment Private Limited has pledged 877,000 shares (5.54%) of Mangalam Drugs & Organics Limited to Badjate Stock Broking Private Limited. This increases Shree Kishoriju's total encumbered holdings to 1,098,515 shares, representing 6.94% of the company's share capital. Director Radhika Ajay Dhoot disclosed this information to stock exchanges in compliance with regulations.
14Aug 25
Mangalam Drugs & Organics' Merger Scheme Receives Strong Backing from Unsecured Creditors
Mangalam Drugs & Organics Limited's proposed merger scheme gained overwhelming support from unsecured creditors at a Tribunal Convened Meeting. The scheme, involving the absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited, received 98.46% approval in value terms. Out of 80 eligible creditors, 36 participated, with 37 voting in favor and 1 against. The Board of Directors is now authorized to proceed with implementing the merger, subject to regulatory approvals.
Mangalam Drugs & Organics
26.20
+1.24
(+4.97%)
1 Year Returns:-77.77%
Industry Peers
Sun Pharmaceutical
1,720.20
(+0.17%)
Divis Laboratories
6,360.50
(-0.47%)
Torrent Pharmaceuticals
3,822.10
(+0.75%)
Cipla
1,492.50
(-0.10%)
Dr Reddys Laboratories
1,265.80
(-0.22%)
Lupin
2,080.40
(-0.08%)
Zydus Life Science
901.45
(-0.35%)
Mankind Pharma
2,152.50
(-1.35%)
Aurobindo Pharma
1,186.30
(-1.15%)
Alkem Laboratories
5,469.00
(-0.65%)